Answer
The population pharmacokinetic analysis of 90 Respreeza-treated subjects in the RAPID trial estimated a mean half-life of 6.8 days.
Sources for this answer
- RespreezaCSL Behring UK Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 11Document updated
Sources checked